Atlas Trials

Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial Cancer

Clinical trial NCT06356155 · RECRUITING

Trial details

NCT number
NCT06356155
Sponsor
University of Michigan Rogel Cancer Center
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Urothelial Carcinoma
Start date
2025-07-22
Primary completion
2028-03-01
Enrollment
32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.